What question did this study set out to answer?

Evaluate the effectiveness and safety of a reduced venetoclax duration combined with decitabine in newly diagnosed AML patients.

December 8, 2025BloodOpen Access

Real-world outcomes of shortened venetoclax course plus decitabine in newly diagnosed acute myeloid leukemia

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis shows reduced venetoclax duration maintains response rates in newly diagnosed AML, suggesting improved safety.

Evaluate the effectiveness and safety of a reduced venetoclax duration combined with decitabine in newly diagnosed AML patients.
Retrospective study of 72 patients with newly diagnosed acute myeloid leukemia.
Patients received decitabine and reduced duration of venetoclax in the AMANDA regimen.
Composite response rates including complete remission and minimal residual disease assessed.
Best complete remission rate was 53%, with an overall response rate of 63%.
Median overall survival was 8.44 months; median event-free survival was 6.18 months.
The regimen showed a lower rate of infections compared to standard regimens.

Jamy et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark